Table 4.
Univariable Associations Between Risk Factors and the Occurrence of CTRCD During the Observation Period
| Sex-Specific cTnT (n = 60) |
Sex-Specific cTnI (n = 18) |
Sex-Neutral cTnT (n = 31) |
Sex-Neutral cTnI (n = 13) |
|||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | |
| Age (per decade) | 1.68 | 1.27-2.22 | 1.46 | 0.78-2.73 | 1.75 | 1.20-2.56 | 1.34 | 0.65-2.76 |
| Systolic blood pressure (per 10 mm Hg) | 1.34 | 1.12-1.62 | 1.25 | 0.79-1.97 | 1.23 | 0.95-1.59 | 1.18 | 0.69-2.02 |
| Epirubicin dose (per 100 mg/m2) | 1.62 | 1.15-2.30 | 1.71 | 0.75-3.91 | 2.32 | 1.40-3.85 | 1.51 | 0.58-3.95 |
| Trastuzumab | 1.57 | 0.89-2.75 | 2.13 | 0.53-8.47 | 2.33 | 1.13-4.80 | 1.64 | 0.34-7.90 |
Mixed-effects logistic regression analyses of risk for CTRCD during adjuvant therapy according to different cTn upper reference limits in the 118 patients who had at least one valid assessment of CTRCD after initiation of anthracyclines. Separate models for each risk factor.
Abbreviations as in Table 3.